82 results
8-K
EX-99.1
RVNC
Revance Therapeutics Inc
9 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
4:08pm
standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio
8-K
EX-99.2
RVNC
Revance Therapeutics Inc
9 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
4:08pm
60,000 people in the United States.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic
424B5
RVNC
Revance Therapeutics Inc
5 Mar 24
Prospectus supplement for primary offering
5:00pm
We are a biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic offerings. Our portfolio includes … our goals;
the extent to which DAXXIFY® and the RHA® Collection of dermal fillers are considered innovative or differentiated;
consumer preferences
424B5
wn9 ax5m8hcgr
4 Mar 24
Prospectus supplement for primary offering
6:39am
8-K
EX-99.1
vrihu9k
28 Feb 24
Provides Corporate Update
4:07pm
8-K
EX-99.1
135 7ihl4fn
8 Jan 24
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
8:01am
S-3ASR
9c8vlg m9gpvcsyl
14 Nov 23
Automatic shelf registration
4:22pm
8-K
EX-99.1
icvlalyn0p qaa
8 Nov 23
Provides Corporate Update
4:09pm
8-K
EX-99.2
flnvl
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-99.1
g5fc22mnslq41 s53cd
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-99.1
6ardy
8 Aug 23
Provides Corporate Update
4:08pm
8-K
EX-99.1
0xsl5pnzyb0fz
9 May 23
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
4:07pm
8-K
EX-99.1
9r4myxxaap v36s
8 Nov 22
Provides Corporate Update
4:06pm